We used four different approaches to detect mutations among the 50 patients with advanced EGFR-mutant lung cancer who acquired resistance to EGFR-TKIs, including ddPCR and NGS assays performed in plasma samples and NGS and Cobas assays performed in tissue samples. This evidence concerns the gene EGFR and lung cancer.